Recalls / Class II
Class IID-1412-2012
Product
Trizivir (abacavir sulfate 300mg, lamivudine 150 mg and zidovudine 300 mg), 60 Tablets, Rx only, Manufactured for: ViiV Healthcare, Research Triangle Park, NC 27709 by: GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 49702-217-18
- Affected lot / code info
- Lot #0ZP5128 exp; 8/2013
Why it was recalled
Adulterated Presence of Foreign Tablets: Trizivir 300/150/300 mg tables, Lot 0ZP5128 may incorrectly contain Lexiva 700 mg tablets.
Recalling firm
- Firm
- GlaxoSmithKline Inc
- Notification channel
- Letter
- Type
- Voluntary: Firm initiated
- Address
- 1011 North Arendell Ave, P.O. Box 1217, Zebulon, North Carolina 27597-1217
Distribution
- Quantity
- 14,465 bottles
- Distribution pattern
- Nationwide
Timeline
- Recall initiated
- 2012-06-04
- FDA classified
- 2012-07-12
- Posted by FDA
- 2012-07-18
- Terminated
- 2014-09-04
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-1412-2012. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.